<p>制造商人寿保险公司在最近向证券交易委员会提交的文件中表示，在第四季度将其在 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免费报告）的持股增加了 7.4%。该公司在此期间购买了 8,576 股后，持有 124,341 股该公司的股票。制造商人寿保险公司在最近的报告期末持有 Protagonist Therapeutics 约 0.21% 的股份，价值 4,800,000 美元。</p>
<ul>
<li>这只小型生物科技股票是否还有更大的收益？</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也对其在 PTGX 的持仓进行了调整。威灵顿管理集团在第四季度将其在 Protagonist Therapeutics 的持股增加了 3,025.4%。威灵顿管理集团现在拥有 940,077 股该公司的股票，价值 36,287,000 美元，此前在上个季度购买了 909,998 股。美国世纪公司在第四季度将其在 Protagonist Therapeutics 的持股增加了 61.5%。美国世纪公司现在拥有 928,286 股该公司的股票，价值 35,832,000 美元，此前在上个季度购买了 353,511 股。首都金融集团在第三季度将其在 Protagonist Therapeutics 的持仓增加了 3,099.4%。首都金融集团现在拥有 320,832 股该公司的股票，价值 14,437,000 美元，此前在上个季度购买了 310,804 股。雷蒙德·詹姆斯金融公司在第四季度购买了 Protagonist Therapeutics 的新股份，价值 11,708,000 美元。最后，Pictet 资产管理控股公司在第四季度将其在 Protagonist Therapeutics 的持仓增加了 3,962.9%。Pictet 资产管理控股公司现在拥有 296,511 股该公司的股票，价值 11,445,000 美元，此前在上个季度购买了 289,213 股。对冲基金和其他机构投资者持有该公司 98.63% 的股票。</p>
<h2>Protagonist Therapeutics 的内部买卖</h2>
<p>在其他消息中，首席执行官 Dinesh V. Ph D. Patel 在 2 月 19 日（星期三）出售了 5,359 股该公司的股票。股票以平均价格 38.18 美元出售，总价值为 204,606.62 美元。出售完成后，首席执行官现在持有 540,260 股该公司的股票，价值约为 20,627,126.80 美元。这代表其持股减少了 0.98%。该出售在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，内部人士 Arturo Md Molina 在 3 月 13 日（星期四）出售了 30,514 股 Protagonist Therapeutics 的股票。股票以平均价格 55.74 美元出售，总交易额为 1,700,850.36 美元。交易后，该内部人士现在直接持有 83,892 股该公司的股票，价值约为 4,676,140.08 美元。这笔交易使其持股减少了 26.67%。该出售的披露信息可以在这里找到。内部人士在过去九十天内共出售了 66,532 股公司股票，价值 3,665,786 美元。公司内部人士持有该公司 5.40% 的股票。</p>
<h2>分析师设定新的价格目标</h2>
<p>一些券商最近对 PTGX 发表了评论。Wedbush 在 3 月 28 日（星期五）的报告中重申了 “跑赢大盘” 的评级，并对 Protagonist Therapeutics 的股票设定了 70.00 美元的价格目标。高盛集团在 2 月 24 日（星期一）的报告中将 Protagonist Therapeutics 的目标价格从 43.00 美元下调至 38.00 美元，并对该公司设定了 “中性” 评级。摩根大通在 3 月 4 日（星期二）的报告中将 Protagonist Therapeutics 的目标价格从 53.00 美元提高至 57.00 美元，并给予该公司 “增持” 评级。JMP 证券在 2 月 7 日（星期五）的研究报告中重申了 “市场跑赢大盘” 的评级，并对 Protagonist Therapeutics 的股票设定了 58.00 美元的价格目标。最后，HC Wainwright 在 4 月 10 日（星期四）的研究报告中重新发布了 “买入” 评级，并对 Protagonist Therapeutics 的股票设定了 80.00 美元的目标价格。两位股票研究分析师对该股票给予了持有评级，七位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 65.44 美元。</p>
<p><strong>获取我们最新的 PTGX 股票分析</strong></p>
<h2>Protagonist Therapeutics 上涨 2.1%</h2>
<p>NASDAQ PTGX 在星期五开盘价为 43.98 美元。该股票的市值为 27.2 亿美元，市盈率为 16.53，贝塔值为 2.65。Protagonist Therapeutics, Inc.的 12 个月低点为 26.79 美元，12 个月高点为 60.60 美元。该公司的 50 日移动平均价格为 46.87 美元，200 日移动平均价格为 42.75 美元。</p>
<p>Protagonist Therapeutics（NASDAQ:PTGX - 获取免费报告）最近在 5 月 6 日（星期二）发布了其财报。该公司报告本季度每股收益为（0.19）美元，超过分析师的共识预期（0.50）美元，超出 0.31 美元。该季度的营业收入为 2832 万美元，而共识预期为 3044 万美元。Protagonist Therapeutics 的净利润率为 52.76%，股本回报率为 34.68%。作为一个整体，卖方分析师预测 Protagonist Therapeutics, Inc.在当前年度将发布 2.43 美元的每股收益。</p>
<h2>Protagonist Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Protagonist Therapeutics, Inc.是一家生物制药公司，开发用于血液学和血液疾病以及炎症和免疫调节疾病的基于肽的药物。该公司正在开发 Rusfertide（PTG-300），这是一种可注射的肝素模仿物，已完成针对真性红细胞增多症和其他血液疾病的二期临床试验；以及 JNJ-2113，这是一种口服给药的研究药物，旨在阻断生物通路，已完成针对中度至重度斑块型银屑病的二期 b 临床试验；以及 PN-943，这是一种口服给药、肠道限制的α4β7 特异性整合素拮抗剂，已在中度至重度溃疡性结肠炎患者中完成二期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Protagonist Therapeutics 更好</li>
<li>技术指标如何帮助你找到被超卖的股票</li>
<li>IBM 的人工智能攻势：评估 IBM 重获增长的路径</li>
<li>每月分红股票的利与弊</li>
<li>罗克韦尔自动化：美国生产回流的顺风</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>能源转移是被低估还是价值陷阱？</li>
</ul>
<p><strong>想看看其他对 PTGX 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Protagonist Therapeutics 吗？</h2>
<p>在你考虑 Protagonist Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前...而 Protagonist Therapeutics 并不在名单上。</p>
<p>虽然 Protagonist Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Protagonist治疗

<p>制造商人寿保险公司将其在 Protagonist Therapeutics, Inc.（纳斯达克代码：PTGX）的股份增加了 7.4%，额外购买了 8,576 股，总持股量达到 124,341 股，价值约为 480 万美元。其他机构投资者也显著增加了他们的持股。内部交易方面，首席执行官 Dinesh V. Ph D. Patel 出售了 5,359 股。分析师对 PTGX 的评级不一，价格目标范围从 38 美元到 80 美元，反映出 “适度买入” 的共识评级。该股票目前交易价格为 43.98 美元，市值为 27.2 亿美元</p>

<p>The Manufacturers Life Insurance Company lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 7.4% during the 4th quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 124,341 shares of the company's stock after purchasing an additional 8,576 shares during the period. The Manufacturers Life Insurance Company owned about 0.21% of Protagonist Therapeutics worth $4,800,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>制造商人寿保险公司在最近向证券交易委员会提交的文件中表示，在第四季度将其在 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免费报告）的持股增加了 7.4%。该公司在此期间购买了 8,576 股后，持有 124,341 股该公司的股票。制造商人寿保险公司在最近的报告期末持有 Protagonist Therapeutics 约 0.21% 的股份，价值 4,800,000 美元。</p>
</div><ul>
<li>Are (More) Big Gains Ahead for This Small Cap Biotech Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>这只小型生物科技股票是否还有更大的收益？</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently made changes to their positions in PTGX. Wellington Management Group LLP lifted its holdings in shares of Protagonist Therapeutics by 3,025.4% in the fourth quarter. Wellington Management Group LLP now owns 940,077 shares of the company's stock worth $36,287,000 after buying an additional 909,998 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Protagonist Therapeutics by 61.5% in the fourth quarter. American Century Companies Inc. now owns 928,286 shares of the company's stock valued at $35,832,000 after purchasing an additional 353,511 shares in the last quarter. Principal Financial Group Inc. increased its position in Protagonist Therapeutics by 3,099.4% in the third quarter. Principal Financial Group Inc. now owns 320,832 shares of the company's stock worth $14,437,000 after purchasing an additional 310,804 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Protagonist Therapeutics during the fourth quarter valued at $11,708,000. Finally, Pictet Asset Management Holding SA lifted its position in Protagonist Therapeutics by 3,962.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 296,511 shares of the company's stock valued at $11,445,000 after purchasing an additional 289,213 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也对其在 PTGX 的持仓进行了调整。威灵顿管理集团在第四季度将其在 Protagonist Therapeutics 的持股增加了 3,025.4%。威灵顿管理集团现在拥有 940,077 股该公司的股票，价值 36,287,000 美元，此前在上个季度购买了 909,998 股。美国世纪公司在第四季度将其在 Protagonist Therapeutics 的持股增加了 61.5%。美国世纪公司现在拥有 928,286 股该公司的股票，价值 35,832,000 美元，此前在上个季度购买了 353,511 股。首都金融集团在第三季度将其在 Protagonist Therapeutics 的持仓增加了 3,099.4%。首都金融集团现在拥有 320,832 股该公司的股票，价值 14,437,000 美元，此前在上个季度购买了 310,804 股。雷蒙德·詹姆斯金融公司在第四季度购买了 Protagonist Therapeutics 的新股份，价值 11,708,000 美元。最后，Pictet 资产管理控股公司在第四季度将其在 Protagonist Therapeutics 的持仓增加了 3,962.9%。Pictet 资产管理控股公司现在拥有 296,511 股该公司的股票，价值 11,445,000 美元，此前在上个季度购买了 289,213 股。对冲基金和其他机构投资者持有该公司 98.63% 的股票。</p>
</div><h2>Insider Buying and Selling at Protagonist Therapeutics</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 的内部买卖</h2>
</div><p>In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now owns 540,260 shares of the company's stock, valued at approximately $20,627,126.80. This represents a 0.98 % decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares in the company, valued at approximately $4,676,140.08. The trade was a 26.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,532 shares of company stock valued at $3,665,786 in the last ninety days. Corporate insiders own 5.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Dinesh V. Ph D. Patel 在 2 月 19 日（星期三）出售了 5,359 股该公司的股票。股票以平均价格 38.18 美元出售，总价值为 204,606.62 美元。出售完成后，首席执行官现在持有 540,260 股该公司的股票，价值约为 20,627,126.80 美元。这代表其持股减少了 0.98%。该出售在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，内部人士 Arturo Md Molina 在 3 月 13 日（星期四）出售了 30,514 股 Protagonist Therapeutics 的股票。股票以平均价格 55.74 美元出售，总交易额为 1,700,850.36 美元。交易后，该内部人士现在直接持有 83,892 股该公司的股票，价值约为 4,676,140.08 美元。这笔交易使其持股减少了 26.67%。该出售的披露信息可以在这里找到。内部人士在过去九十天内共出售了 66,532 股公司股票，价值 3,665,786 美元。公司内部人士持有该公司 5.40% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of brokerages recently commented on PTGX. Wedbush reaffirmed an &#34;outperform&#34; rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a report on Friday, March 28th. The Goldman Sachs Group dropped their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a &#34;neutral&#34; rating for the company in a report on Monday, February 24th. JPMorgan Chase &amp; Co. increased their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, March 4th. JMP Securities reaffirmed a &#34;market outperform&#34; rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $65.44.</p>
<div class="lb-trans"><p>一些券商最近对 PTGX 发表了评论。Wedbush 在 3 月 28 日（星期五）的报告中重申了 “跑赢大盘” 的评级，并对 Protagonist Therapeutics 的股票设定了 70.00 美元的价格目标。高盛集团在 2 月 24 日（星期一）的报告中将 Protagonist Therapeutics 的目标价格从 43.00 美元下调至 38.00 美元，并对该公司设定了 “中性” 评级。摩根大通在 3 月 4 日（星期二）的报告中将 Protagonist Therapeutics 的目标价格从 53.00 美元提高至 57.00 美元，并给予该公司 “增持” 评级。JMP 证券在 2 月 7 日（星期五）的研究报告中重申了 “市场跑赢大盘” 的评级，并对 Protagonist Therapeutics 的股票设定了 58.00 美元的价格目标。最后，HC Wainwright 在 4 月 10 日（星期四）的研究报告中重新发布了 “买入” 评级，并对 Protagonist Therapeutics 的股票设定了 80.00 美元的目标价格。两位股票研究分析师对该股票给予了持有评级，七位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，共识目标价格为 65.44 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on PTGX</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 PTGX 股票分析</strong></p>
</div><h2>Protagonist Therapeutics Trading Up 2.1 %</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 上涨 2.1%</h2>
</div><p>NASDAQ PTGX opened at $43.98 on Friday. The stock has a market cap of $2.72 billion, a PE ratio of 16.53 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 12 month low of $26.79 and a 12 month high of $60.60. The company's 50-day moving average price is $46.87 and its 200-day moving average price is $42.75.</p>
<div class="lb-trans"><p>NASDAQ PTGX 在星期五开盘价为 43.98 美元。该股票的市值为 27.2 亿美元，市盈率为 16.53，贝塔值为 2.65。Protagonist Therapeutics, Inc.的 12 个月低点为 26.79 美元，12 个月高点为 60.60 美元。该公司的 50 日移动平均价格为 46.87 美元，200 日移动平均价格为 42.75 美元。</p>
</div><p>Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. The business had revenue of $28.32 million for the quarter, compared to the consensus estimate of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. As a group, sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.</p>
<div class="lb-trans"><p>Protagonist Therapeutics（NASDAQ:PTGX - 获取免费报告）最近在 5 月 6 日（星期二）发布了其财报。该公司报告本季度每股收益为（0.19）美元，超过分析师的共识预期（0.50）美元，超出 0.31 美元。该季度的营业收入为 2832 万美元，而共识预期为 3044 万美元。Protagonist Therapeutics 的净利润率为 52.76%，股本回报率为 34.68%。作为一个整体，卖方分析师预测 Protagonist Therapeutics, Inc.在当前年度将发布 2.43 美元的每股收益。</p>
</div><h2>Protagonist Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Protagonist Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.</p>
<div class="lb-trans"><p>Protagonist Therapeutics, Inc.是一家生物制药公司，开发用于血液学和血液疾病以及炎症和免疫调节疾病的基于肽的药物。该公司正在开发 Rusfertide（PTG-300），这是一种可注射的肝素模仿物，已完成针对真性红细胞增多症和其他血液疾病的二期临床试验；以及 JNJ-2113，这是一种口服给药的研究药物，旨在阻断生物通路，已完成针对中度至重度斑块型银屑病的二期 b 临床试验；以及 PN-943，这是一种口服给药、肠道限制的α4β7 特异性整合素拮抗剂，已在中度至重度溃疡性结肠炎患者中完成二期临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Protagonist Therapeutics</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>IBM's AI Offensive: Assessing IBM's Path to Renewed Growth</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>Rockwell Automation: Tailwinds From Onshoring U.S. Production</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Is Energy Transfer Undervalued or a Value Trap?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Protagonist Therapeutics 更好</li>
<li>技术指标如何帮助你找到被超卖的股票</li>
<li>IBM 的人工智能攻势：评估 IBM 重获增长的路径</li>
<li>每月分红股票的利与弊</li>
<li>罗克韦尔自动化：美国生产回流的顺风</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>能源转移是被低估还是价值陷阱？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PTGX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 PTGX 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com，获取 Protagonist Therapeutics, Inc.（NASDAQ:PTGX - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PTGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Protagonist Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Protagonist Therapeutics 吗？</h2>
</div><p>Before you consider Protagonist Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Protagonist Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前...而 Protagonist Therapeutics 并不在名单上。</p>
</div><p>While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Protagonist Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

制造商人寿保险公司购入了 8,576 股 Protagonist Therapeutics, Inc.（NASDAQ:PTGX）的股票